参考文献/References:
[1] XIA Changfa, DONG Xuesi, LI He, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chinese Medical Journal, 2022, 135(5): 584-590.
[2] SHUKUYA T, CARBONE D P. Predictive markers for the efficacy of anti-PD-1/PD-L1 antibodies in lung cancer[J]. Journal of Thoracic Oncology, 2016, 11(7): 976-988.
[3] LEE J S, RUPPIN E. Multiomics prediction of response rates to therapies to inhibit programmed cell death 1 and programmed cell death 1 ligand 1[J]. JAMA Oncology, 2019, 5(11): 1614-1618.
[4] GALON J, PAG?S F, MARINCOLA F M, et al. Cancer classification using the immunoscore: a worldwide task force [J]. Journal of Translational Medicine, 2012, 10: 205.
[5] MAZZASCHI G, MINARI R, ZECCA A, et al. Soluble PD-L1 and circulating CD8+PD-1+ and NK cells enclose a prognostic and predictive immune effector score in immunotherapy treated NSCLC patients [J].Lung Cancer, 2020, 148: 1-11.
[6] GALON J, COSTES A, SANCHEZ-CABO F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome[J].Science, 2006, 313(5795): 1960-1964.
[7] FRIDMAN W H, PAG?S F, SAUT?S-FRIDMAN C, et al. The immune contexture in human tumours: impact on clinical outcome[J]. Nature Reviews Cancer, 2012, 12(4): 298-306.
[8] MAZZASCHI G, FACCHINETTI F, MISSALE G, et al. The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC [J]. Lung Cancer, 2019, 127: 153-163.
[9] INOMATA M, KADO T, OKAZAWA S, et al. Peripheral pd1-positive cd4 t-lymphocyte count can predict progression-free survival in patients with nonsmall cell lung cancer receiving immune checkpoint inhibitor[J]. Anticancer Research, 2019, 39(12): 6887-6893.
[10] TANIZAKI J, HARATANI K, HAYASHI H, et al. Peripheral blood biomarkers associated with clinical outcome in non-small cell lung cancer patients treated with nivolumab[J]. Journal of Thoracic Oncology, 2018, 13(1): 97-105.
[11] ZHANG Zhibo, LI Ye, YAN Xiang, et al. Pretreatment lactate dehydrogenase may predict outcome of advanced non small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis[J].Cancer Medicine, 2019, 8(4): 1467-1473.
[12] 夏经纬, 陈羽中, 温少迪, 等. 外周血炎症指标作为预测性指标在晚期非小细胞肺癌免疫治疗中的应用[J]. 中国肺癌杂志, 2021, 24(9): 632-645. XIA Jingwei, CHEN Yuzhong, WEN Shaodi, et al. Peripheral blood inflammation indicators as predictive indicators in immunotherapy of advanced non-small cell lung cancer [J]. Chinese Journal of Lung Cancer, 2021, 24(9): 632-645.
[13] ARKENAU H T, OLMOS D, ANG J E, et al. 90-days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial?[J]. European Journal of Cancer, 2008, 44(11): 1536-1540.
[14] ARKENAU H T, OLMOS D, ANG J E, et al. Clinical outcome and prognosic factors for patients treated within the context of a phase I study: the Royal Marsden Hosptal experience[J]. British Journal of Cancer, 2008, 98(6): 1029-1033.
[15] LIU J, WU Q, WU S, et al. Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs)[J]. Clinical and Translational Oncology, 2021, 23(9):1782-1793.
[16] ARKENAU H T, BARRIUSO J, OLMOS D, et al. Prospective validation of a prognostic score to improve patient selection for oncology phase I trials[J]. Journal of Clinical Oncology, 2009, 27(16): 2692-2696.
[17] MASSARD C, BORGET I, LE DELEY M C, et al. Prognostic value of circulating VEGFR2+ bone marrowderived progenitor cells in patients with advanced cancer[J]. European Journal of Cancer, 2012, 48(9): 1354-1362.
[18] MARTINI D J, LIU Yuan, SHABTO J M, et al. Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials[J].Investigational New Drugs, 2019, 37(6): 1198-1206.
[19] BIGOT F, CASTANON E, BALDINI C, et al. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: the Gustave Roussy immune score (GRIm-Score) [J]. European Journal of Cancer, 2017, 84: 212-218.
[20] MINAMI S, IHARA S, IKUTA S, et al. Gustave roussy immune score and royal marsden hospital prognostic score are biomarkers of immune-checkpoint inhibitor for non-small cell lung cancer[J]. World Journal of Oncology, 2019, 10(2): 90-100.
[21] LENCI E, CANTINI L, PECCI F, et al. The gustave roussy immune (GRIm)-score variation is an early-ontreatment biomarker of outcome in advanced non-small cell lung cancer (NSCLC) patients treated with firstline pembrolizumab[J]. Journal of Clinical Medicine, 2021, 10(5): 1005.
[22] MINAMI S, IHARA S, KOMUTA K. Gustave roussy immune score is a prognostic factor for chemotherapynaive pulmonary adenocarcinoma with wild-type epidermal growth factor receptor[J]. World Journal of Oncology, 2019, 10(1): 55-61.
[23] LI Shuangjiang, ZHAO Liang, WANG Hongyu, et al. Gustave roussy immune score based on a three-category risk assessment scale serves as a novel and effective prognostic indicator for surgically resectable earlystage non-small-cell lung cancer: a propensity score matching retrospective cohort study [J]. International Journal of Surgery, 2020, 84: 25-40.
[24] MINAMI S, IHARA S, KOMUTA K. Gustave roussy immune score and royal marsden hospital prognostic score are prognostic markers for extensive disease of small cell lung cancer[J]. World Journal of Oncology, 2020, 11(3): 98-105.
[25] ZHANG Yi, CHEN Bo, WANG Lijuan, et al. Systemic immune-inflammation index is a promising noninvasive marker to predict survival of lung cancer: a metaanalysis[J]. Medicine, 2019, 98(3): e13788.
[26] FENG Jifeng, WANG Liang, YANG Xun, et al. Gustave roussy immune score (GRIm-score) is a prognostic marker in patients with resectable esophageal squamous cell carcinoma[J]. Journal of Cancer, 2020, 11(6): 1334-1340.
[27] TIAN Shan, CAO Yinghao, DUAN Yanran, et al. Gustave roussy immune score as a novel prognostic scoring system for colorectal cancer patients: a propensity score matching analysis[J]. Frontiers in Oncology, 2021, 11: 737283.
[28] HU Bo, YANG Xinrong, XU Yang, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma[J]. Clinical Cancer Research, 2014, 20(23): 6212-6222.
[29] JOMRICH G, GRUBER E S, WINKLER D, et al. Systemic immune-inflammation index (SII) predicts poor survival in pancreatic cancer patients undergoing resection[J]. Journal of Gastrointestinal Surgery, 2020, 24(3): 610-618.
[30] TERASAKI F, SUGIURA T, OKAMURA Y, et al. Systemic immune-inflammation index as a prognostic marker for distal cholangiocarcinoma[J]. Surgery Today, 2021, 51(10): 1602-1609.
[31] LI Wen, MA Guangzhi, DENG Yunfu, et al. Systemic immune-inflammation index is a prognostic factor for breast cancer patients after curative resection [J].Frontiers in Oncology, 2021, 11: 570208.
[32] XU Jianjun, HU Shaobo, LI Suzhen, et al. Systemic immune-inflammation index predicts postoperative acute kidney injury in hepatocellular carcinoma patients after hepatectomy[J]. Medicine, 2021, 100(14): e25335.
[33] FU Fangqiu, DENG Chaoqiang, WEN Zhexu, et al. Systemic immune-inflammation index is a stagedependent prognostic factor in patients with operable non-small cell lung cancer[J]. Translational Lung Cancer Research, 2021, 10(7): 3144-3154.
[34] YEKED?Z E, DOGAN ?, KAYA D M, et al. Systemic immune-inflammation index as a prognostic marker of late recurrence in operable gastric cancer: a dual-center study[J]. Journal of Gastrointestinal Cancer, 2022, 53(4): 870-879.
[35] JAFRI S H, SHI Runhua, MILLS G. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review[J].BMC Cancer, 2013, 13: 158.
[36] BACHA S, SGHAIER A, HABIBECH S, et al. Advanced lung cancer inflammation index: a prognostic score in patients with metastatic non-small cell lung cancer[J]. La Tunisie Medicale, 2017, 95(11): 976-981.
[37] LU Ping, MA Yifei, KAI Jindan, et al. A low advanced lung cancer inflammation index predicts a poor prognosis in patients with metastatic non-small cell lung cancer [J]. Frontiers in Molecular Biosciences, 2021, 8: 784667.
[38] HUA Xin, CHEN Jing, WU Ying, et al. Prognostic role of the advanced lung cancer inflammation index in cancer patients: a meta-analysis[J]. World Journal of Surgical Oncology, 2019, 17(1): 177.
[39] ALDEA M, BENITEZ J C, MEZQUITA L. The lung immune prognostic index (LIPI) stratifies prognostic groups in advanced non-small cell lung cancer (NSCLC) patients[J]. Translational Lung Cancer Research, 2020, 9(4): 967-970.
[40] HUANG Litang, HAN Hedong, ZHOU Li, et al. Evaluation of the lung immune prognostic index in nonsmall cell lung cancer patients treated with systemic therapy: a retrospective study and meta-analysis[J].Frontiers in Oncology, 2021, 11: 670230.
[41] PARK W, KWON D, SARAVIA D, et al. Developing a predictive model for clinical outcomes of advanced non-small cell lung cancer patients treated with nivolumab[J]. Clinical Lung Cancer, 2018, 19(3): 280-288, e4.
[42] PARK W, MEZQUITA L, OKABE N, et al. Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer[J].British Journal of Cancer, 2020, 122(3): 340-347.
[43] 陈香萍, 张奕, 庄一渝, 等. PROBAST: 诊断或预后多因素预测模型研究偏倚风险的评估工具[J]. 中国循证医学杂志, 2020, 20(6): 737-744. CHEN Xiangping, ZHANG Yi, ZHUANG Yiyu, et al. PROBAST: a tool for assessing risk of bias in the study of diagnostic or prognostic multi-factorial predictive models[J]. Chinese Journal of Evidence-Based medicine, 2020, 20(6): 737-744.
[44] LIU Jingjing, LI Shuang, ZHANG Shuang, et al. Systemic immune-inflammation index, neutrophilto-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab[J].Journal of Clinical Laboratory Analysis, 2019, 33(8): e22964.
[45] SHIROYAMA T, SUZUKI H, TAMIYA M, et al. Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumabtreated patients with advanced non-small cell lung cancer[J]. Cancer Medicine, 2018, 7(1): 13-20.
[46] RUIZ-BA?OBRE J, ARESES-MANRIQUE M C, MOSQUERA-MART?NEZ J, et al. Evaluation of the lung immune prognostic index in advanced nonsmall cell lung cancer patients under nivolumab monotherapy[J]. Translational Lung Cancer Research, 2019, 8(6): 1078-1085.
[47] WEST H, MCCLEOD M, HUSSEIN M, et al. Atezolizumab in combination with carboplatin plus nabpaclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic nonsquamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial[J].Lancet Oncology, 2019, 20(7): 924-937.
[48] YUAN Zhijun, WENG Shanshan, YE Chenyang, et al. CSCO guidelines for colorectal cancer version 2022: Updates and discussions[J]. Chinese Journal of Cancer Research, 2022, 34(2): 67-70.
[49] MOUNTZIOS G, SAMANTAS E, SENGHAS K, et al. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer [J].ESMO Open, 2021, 6(5): 100254.
[50] HOPKINS A M, KICHENADASSE G, ABUHELWA A Y, et al. Value of the lung immune prognostic index in patients with non-small cell lung cancer initiating first-line atezolizumab combination therapy: subgroup analysis of the IMPOWER150 trial[J]. Cancers, 2021, 13(5): 1176.
[51] WANG Wenxian, HUANG Zhangzhou, YU Zongyang, et al. Prognostic value of the lung immune prognostic index may differ in patients treated with immune checkpoint inhibitor monotherapy or combined with chemotherapy for non-small cell lung cancer[J].Frontiers in Oncology, 2020, 10: 572853.
[52] DENG Chao, ZHANG Na, WANG Yapeng, et al. High systemic immune-inflammation index predicts poor prognosis in advanced lung adenocarcinoma patients treated with EGFR-TKIs[J]. Medicine, 2019, 98(33): e16875.
[53] CHANTHARAKHIT C, SUJARITVANICHPONG N. Prognostic impact of the advanced lung cancer inflammation index (ALI) in metastatic non-small cell lung cancer treated with first line chemotherapy[J].Asian Pacific Journal of Cancer Prevention, 2021, 22(4): 1149-1156.
[54] HAN Zhaohui, HU Zhonghui, ZHAO Qingtao, et al. The advanced lung cancer inflammation index predicts outcomes of patients with non-small cell lung cancer following video-assisted thoracic surgery[J]. Journal of International Medical Research, 2021, 49(12): 3000605211062442.
[55] WANG Jianyang, HUI Zhouguang, MEN Yu, et al. Systemic inflammation-immune status predicts survival in stage III-N2 non-small cell lung cancer[J]. Annals of Thoracic Surgery, 2019, 108(6): 1701-1709.
[56] GAO Yongyin, ZHANG Hongdian, LI Yue, et al. Preoperative increased systemic immune-inflammation index predicts poor prognosis in patients with operable non-small cell lung cancer [J]. Clinica Chimica Acta, 2018, 484: 272-277.
[57] TOMITA M, AYABE T, MAEDA R, et al. Comparison of inflammation-based prognostic scores in patients undergoing curative resection for non-small cell lung cancer[J]. World Journal of Oncology, 2018, 9(3): 85-90.
[58] KAZANDJIAN D, GONG Yutao, KEEGAN P, et al. Prognostic value of the lung immune prognostic index for patients treated for metastatic non-small cell lung cancer[J]. JAMA Oncology, 2019, 5(10): 1481-1485.
[59] 张玲玲, 张小霞, 於潇潇, 等. 非小细胞肺癌患者血浆miR-520f, miR-143-3p 表达与病理特征和预后的相关性研究[J]. 现代检验医学杂志, 2022, 37(3): 69-72, 78. ZHANG Lingling, ZHANG Xiaoxia, YU Xiaoxiao, et al. Correlation study on plasma miR-520f and miR-143-3p expression with pathological features and prognosis in patients with non-small cell lung cancer [J]. Journal of Modern Laboratory Medicine, 2022, 37(3): 69-72, 78.
[60] 刘延梅, 马少君, 马庆, 等. 非小细胞肺癌患者组织EGFR 基因突变状况及预后分析[J]. 现代检验医学杂志, 2019, 34(1): 22-25. LIU Yanmei, MA Shaojun, MA Qing, et al. Analysis of the status and outcome of epidermal growth factor receptor mutations in non-small cell lung cancer patients [J]. Journal of Modern Laboratory Medicine, 2019, 34(1): 22-25.
[61] MAZZASCHI G, MINARI R, ZECCA A, et al. Soluble PD-L1 and circulating CD8+PD-1+ and NK cells enclose a prognostic and predictive immune effector score in immunotherapy treated NSCLC patients [J].Lung Cancer, 2020, 148: 1-11.
相似文献/References:
[1]张 蕾,任亚女,曾婷婷,等.晚期非小细胞肺癌患者血液实验指标和病理分期等因素对生存时间的影响分析[J].现代检验医学杂志,2016,31(02):83.[doi:10.3969/j.issn.1671-7414.2016.02.025]
ZHANG Lei,REN Ya-n,ZENG Ting-ting,et al.Analysis of Prognosis Related Factors in Patients
with Advanced Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(01):83.[doi:10.3969/j.issn.1671-7414.2016.02.025]
[2]薛鸿涛,任 敏,李长彬.非小细胞肺癌患者放疗前后血清TSGF和CRP的变化及其临床意义[J].现代检验医学杂志,2016,31(02):136.[doi:10.3969/j.issn.1671-7414.2016.02.041]
XUE Hong-tao,REN Min,LI Chang-bin.Impact and Clinical Significance of Radiotherapy on Serum
TSGF and CRP in Patients with Non Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(01):136.[doi:10.3969/j.issn.1671-7414.2016.02.041]
[3]王京伟,李 艳,童永清,等.湖北地区非小细胞肺癌EGFR 基因突变及其意义的研究[J].现代检验医学杂志,2016,31(03):7.[doi:10.3969/j.issn.1671-7414.2016.03.003]
WANG Jing-wei,LI Yan,TONG Yong-qing,et al.Detection of Epidermal Growth Factor Receptor(EGFR)
Mutations and the Significance in Patients with Non-small Cell Lung
Cancer(NSCLC)of Hubei Province[J].Journal of Modern Laboratory Medicine,2016,31(01):7.[doi:10.3969/j.issn.1671-7414.2016.03.003]
[4]易甲其,范艳平,周宁加,等.血清PTX-3，CYFRA21-1和TPS在非小细胞肺癌中的变化及临床意义[J].现代检验医学杂志,2015,30(05):58.[doi:10.3969/j.issn.1671-7414.2015.05.018]
YI Jia-qi,FAN Yan-ping,ZHOU Ning-jia,et al.Changes and Clinical Significance of Serum PTX-3，
CYFRA21-1，TPS in Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2015,30(01):58.[doi:10.3969/j.issn.1671-7414.2015.05.018]
[5]钱忠萍,凌 晨,祁松楠,等.围非小细胞肺癌手术期T细胞含量变化的研究[J].现代检验医学杂志,2016,31(05):55.[doi:10.3969/j.issn.1671-7414.2016.05.014]
QIAN Zhong-ping,LING Chen,QI Song-nan,et al.Content Variation of T Cells in Perioperative Patients
with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(01):55.[doi:10.3969/j.issn.1671-7414.2016.05.014]
[6]黎谢梦丹,罗 凯,吴顺芳,等.华南地区非小细胞肺癌患者肿瘤组织EGFR,ALK和ROS1基因突变分析[J].现代检验医学杂志,2017,32(05):16.[doi:10.3969/j.issn.1671-7414.2017.05.005]
LIXIE Meng-dan,LUO Kai,WU Shun-fang,et al.Mutation Analysis of EGFR,ALK and ROS1 in Tumor Tissues
of Patients with Non-Small Cell Lung Cancer in South of China[J].Journal of Modern Laboratory Medicine,2017,32(01):16.[doi:10.3969/j.issn.1671-7414.2017.05.005]
[7]李小龙,白巧艳,陆婉玲.老年非小细胞肺癌患者低分割放疗对凝血功能的影响[J].现代检验医学杂志,2018,33(05):142.[doi:10.3969/j.issn.1671-7414.2018.05.039]
LI Xiao-long,BAI Qiao-yan,LU Wan-ling.Influence of Hypofractionated High-Dose Radiotherapy on Coagulation Function in Elderly Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2018,33(01):142.[doi:10.3969/j.issn.1671-7414.2018.05.039]
[8]郭 华a,齐宗利a,张海祥b,等.非小细胞肺癌组织EGFR/ALK/ROS1基因联合检测的临床意义[J].现代检验医学杂志,2018,33(06):17.[doi:10.3969/j.issn.1671-7414.2018.06.005]
GUO Huaa,QI Zong-lia,ZHANG Hai-xiangb,et al.Clinical Significance of Combined Detection of EGFR/ALK/ROS1 Genes in Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2018,33(01):17.[doi:10.3969/j.issn.1671-7414.2018.06.005]
[9]黄 刚,陈 霏,肇玉博,等.非小细胞肺癌患者血浆miRNA-145和miRNA-221表达与临床特征及术后复发的相关性研究[J].现代检验医学杂志,2019,34(04):40.[doi:10.3969/j.issn.1671-7414.2019.04.010]
HUANG Gang,CHEN Fei,ZHAO Yu-bo,et al.Study on the Correlation between the Expression of MicroRNA145
and MicroRNA221 in Plasma and Clinical Characteristics and
Postoperative Recurrence in Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2019,34(01):40.[doi:10.3969/j.issn.1671-7414.2019.04.010]
[10]蒋玲丽,黄中强,王雪亮,等.表皮生长因子受体（EGFR）基因突变检测质控品制备及应用[J].现代检验医学杂志,2020,35(02):145.[doi:10.3969/j.issn.1671-7414.2020.02.040]
JIANG Ling-li,HUANG Zhong-qiang,WANG Xue-liang,et al.Development and Application of Quality Control Materials for EpidermalGrowth Factor Receptor （EGFR）Mutation Determination[J].Journal of Modern Laboratory Medicine,2020,35(01):145.[doi:10.3969/j.issn.1671-7414.2020.02.040]